There are many rare diseases that originate with a single letter change in DNA, and they can cause tremendous physical and financial hardship for families affected. Viral-based gene therapies have been a promise for decades, and modern technology is now bringing these concepts to fruition. Dr. Gaurav Shah, CEO of Rocket Pharma, describes the power of the current gene therapy approaches, along with the pipeline of potential therapeutics that could represent cures for rare disease.